Dx & Vx Co

Dx & Vx Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Dx & Vx Co (180400.KQ) as of Nov 3, 2026 is 69.80 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 44.35 % — a change of 57.38% (higher).

FCF Conversion

69.80 %

YoY

57.38%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Dx & Vx Co is 2025 69.80 % . FCF Conversion Rate (FCF/EBITDA) of Dx & Vx Co was 2024 44.35 % . It decreases by 57.38% higher compared to the previous year.

The Dx & Vx Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
169.77 KRW
Jan 1, 2019
46.79 KRW
Jan 1, 2020
113.75 KRW
Jan 1, 2021
51.77 KRW
Jan 1, 2022
111.98 KRW
Jan 1, 2023
51.84 KRW
Jan 1, 2024
44.35 KRW
Jan 1, 2025
69.80 KRW
The Dx & Vx Co FCF Conversion history
YEARFCF ConversionYoY
69.80 %+57.38%
44.35 %-14.44%
51.84 %-53.71%
111.98 %+116.31%
51.77 %-54.49%
113.75 %+143.08%
46.79 %-72.44%
169.77 %-9.45%
187.49 %-54.68%
413.69 %-336.03%
-175.27 %-178.07%
224.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

FCF Conversion Rate (FCF/EBITDA) of Dx & Vx Co is 69.80 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Dx & Vx Co changed from 44.35 % to 69.80 %, representing a 57.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Dx & Vx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dx & Vx Co

All Key Metrics — Dx & Vx Co